ENDP

Endo International plc [ENDP] Stock Forecast

Q: What is Endo International plc stock symbol ?

Endo International plc is a IE stock, located in Dublin of Dublin and trading under the symbol ENDP

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ENDP Stock Summary

The Moving Average Convergence Divergence (MACD) for ENDP recently turned positive (within last 10 days).

Earnings are expected to fall -100% next year

ENDP has less than 1 year of cash runway

In the News

ENDP Financial details

Company Rating

Neutral

Market Cap

Income

-2.58B

Revenue

2.78B

Book val./share

-12.33

Cash/share

5.07

Dividend

Dividend %

Employees

3.1K

Optionable

Shortable

Yes

Earnings

09 Aug 2022

P/E

-0.15

Forward P/E

PEG

P/S

P/B

-0.07

P/C

0.06

P/FCF

Quick Ratio

1.29

Current Ratio

1.67

Debt / Equity

-2.8

LT Debt / Equity

-2.79

EPS (TTM)

-11.01

EPS next Y

EPS next Q

EPS this Y

-408.86%

EPS next Y

EPS next 5Y

EPS last 5Y

-23.18%

Revenue last 5Y

-2.91%

Revenue Q/Q

-12.75%

EPS Q/Q

2764.29%

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

-6%

ROE

60%

ROC

Gross Margin

59%

Oper. Margin

Profit Margin

-19%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

52W High

52W Low

RSI

Rel Volume

Avg Volume

Volume

39.16M

Perf Week

Perf Month

Perf Quarter

Perf Half Y

-21.85%

Beta

1.15331

Volatility

0%, 0.1%

Prev Close

Price

0.2926

Change

-3.34%

ENDP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	15.54	13.16	12.89	12.42	12.86
Net income per share	-9.12	-4.61	-1.87	0.79	-2.44
Operating cash flow per share	2.48	1.19	0.43	1.7	1.77
Free cash flow per share	1.92	0.81	0.15	-1.39	1.43
Cash per share	4.42	5.13	6.43	5.19	6.47
Book value per share	2.17	-2.22	-3.83	-2.77	-5.34
Tangible book value per share	-37.11	-34.47	-31.11	-29.74	-23.88
Share holders equity per share	2.17	-2.22	-3.83	-2.77	-5.34
Interest debt per share	39.3	39.26	39.65	37.93	37.13
Market cap	1.73B	1.63B	1.06B	1.68B	875.27M
Enterprise value	9.02B	8.74B	8.01B	8.79B	7.45B
P/E ratio	-0.85	-1.59	-2.51	9.12	-1.54
Price to sales ratio	0.5	0.55	0.36	0.58	0.29
POCF ratio	3.12	6.12	10.81	4.22	2.13
PFCF ratio	4.04	9.04	31	-5.18	2.63
P/B Ratio	3.57	-3.28	-1.22	-2.59	-0.7
PTB ratio	3.57	-3.28	-1.22	-2.59	-0.7
EV to sales	2.6	2.97	2.75	3.03	2.49
Enterprise value over EBITDA	-11.17	34.97	10.48	9.1	15.76
EV to operating cash flow	16.28	32.72	81.7	22.12	18.12
EV to free cash flow	21.06	48.34	234.24	-27.12	22.36
Earnings yield	-1.18	-0.63	-0.4	0.11	-0.65
Free cash flow yield	0.25	0.11	0.03	-0.19	0.38
Debt to equity	17.07	-16.57	-9.7	-12.85	-6.5
Debt to assets	0.71	0.82	0.9	0.9	0.92
Net debt to EBITDA	-9.03	28.43	9.09	7.36	13.9
Current ratio	1.02	1.2	1.77	1.92	1.67
Interest coverage	-1.94	-0.88	1.04	1.12	0.03
Income quality	-0.27	-0.26	-0.23	2.16	-0.72
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.18	0.22	0.22	0.24	0
Research and developement to revenue	0.05	0.06	0.04	0.05	0.05
Intangibles to total assets	0.75	0.71	0.66	0.68	0.63
Capex to operating cash flow	-0.23	-0.32	-0.65	-1.82	-0.19
Capex to revenue	-0.04	-0.03	-0.02	-0.25	-0.03
Capex to depreciation	-0.13	-0.12	-0.1	-1.39	-0.17
Stock based compensation to revenue	0.01	0.02	0.02	0.01	0.01
Graham number	21.11	15.18	12.7	7.01	17.14
ROIC	-0.09	-0.06	0.08	-0.73	0
Return on tangible assets	-0.71	-0.35	-0.13	0.06	-0.18
Graham Net	-42.88	-39.91	-36.5	-34.63	-28.67
Working capital	50.17M	393.05M	1.13B	1.16B	1.08B
Tangible asset value	-8.28B	-7.72B	-7.03B	-6.95B	-5.56B
Net current asset value	-8.88B	-8.29B	-7.67B	-7.5B	-6.05B
Invested capital	17.07	-16.57	-9.7	-12.85	-6.5
Average receivables	784.72M	519.92M	512.94M	545.31M	583.56M
Average payables	106.03M	90.69M	98.78M	97.97M	47.2M
Average inventory	473.55M	356.81M	325.02M	340.06M	317.91M
Days sales outstanding	55.71	63.21	64.56	72.31	72.19
Days payables outstanding	13.98	21.48	23.61	23.89	0
Days of inventory on hand	64.11	72.07	76.26	89.13	84.76
Receivables turnover	6.55	5.77	5.65	5.05	5.06
Payables turnover	26.11	16.99	15.46	15.28	0
Inventory turnover	5.69	5.06	4.79	4.1	4.31
ROE	-4.2	2.07	0.49	-0.28	0.46
Capex per share	-0.56	-0.39	-0.28	-3.09	-0.33

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric	2021-06-30	2021-09-30	2021-12-31	2022-03-31	2022-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.06	3.31	3.38	2.79	2.42
Net income per share	-0.07	-0.33	-2.38	-0.28	-8.02
Operating cash flow per share	0.66	0.27	-0.21	0.86	0
Free cash flow per share	0.55	0.16	-0.25	0.66	0
Cash per share	6.62	6.72	6.45	6.04	5.07
Book value per share	-2.64	-2.96	-5.32	-5.61	-12.33
Tangible book value per share	-28.82	-28.7	-23.79	-28.91	-27.57
Share holders equity per share	-2.64	-2.96	-5.32	-5.61	-12.33
Interest debt per share	36.27	36.23	35.2	35.25	35.07
Market cap	1.09B	756.79M	878.64M	540.26M	109.49M
Enterprise value	7.87B	7.51B	7.45B	7.24B	7.02B
P/E ratio	-17.61	-2.45	-0.39	-2.07	-0.01
Price to sales ratio	1.53	0.98	1.11	0.83	0.19
POCF ratio	7.05	12.19	-17.62	2.68	0
PFCF ratio	8.54	20.48	-14.94	3.51	0
P/B Ratio	-1.77	-1.1	-0.71	-0.41	-0.04
PTB ratio	-1.77	-1.1	-0.71	-0.41	-0.04
EV to sales	11.02	9.73	9.44	11.1	12.34
Enterprise value over EBITDA	30.68	41.69	-25.06	43.18	-3.73
EV to operating cash flow	50.77	120.91	-149.47	35.95	0
EV to free cash flow	61.52	203.23	-126.73	47.06	0
Earnings yield	-0.01	-0.1	-0.63	-0.12	-17.22
Free cash flow yield	0.12	0.05	-0.07	0.28	0
Debt to equity	-13.48	-12.05	-6.5	-6.19	-2.8
Debt to assets	0.9	0.9	0.92	0.96	1.27
Net debt to EBITDA	26.42	37.49	-22.11	39.96	-3.68
Current ratio	1.82	1.77	1.67	1.81	1.86
Interest coverage	1.29	1.49	-2.82	0.45	-12.4
Income quality	-10	-0.8	0.09	-2.8	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.05	0.03	0.07	0.06	0.05
Intangibles to total assets	0.66	0.65	0.63	0.65	0.56
Capex to operating cash flow	-0.17	-0.41	0.18	-0.24	0
Capex to revenue	-0.04	-0.03	-0.01	-0.07	0
Capex to depreciation	-0.23	-0.22	-0.08	-0.45	0
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0
Graham number	1.99	4.69	16.89	5.93	47.16
ROIC	-0.26	0.03	-0.06	0.01	-0.33
Return on tangible assets	-0.01	-0.02	-0.17	-0.02	-0.68
Graham Net	-33.25	-33.44	-28.56	-33.53	-32.14
Working capital	1.16B	1.19B	1.08B	1.12B	1.02B
Tangible asset value	-6.73B	-6.7B	-5.56B	-6.76B	-6.48B
Net current asset value	-7.25B	-7.19B	-6.05B	-7.27B	-7.06B
Invested capital	-13.48	-12.05	-6.5	-6.19	-2.8
Average receivables	475.04M	506M	568.05M	537.34M	487.07M
Average payables	104.18M	107.44M	55.52M	50.5M	50.5M
Average inventory	350.32M	317.88M	290.43M	283.69M	285.79M
Days sales outstanding	59	63.43	67.49	66.6	77.72
Days payables outstanding	29.34	34.94	0	33.27	0
Days of inventory on hand	95.65	93.53	82	93.5	98.18
Receivables turnover	1.53	1.42	1.33	1.35	1.16
Payables turnover	3.07	2.58	0	2.7	0
Inventory turnover	0.94	0.96	1.1	0.96	0.92
ROE	0.03	0.11	0.45	0.05	0.65
Capex per share	-0.12	-0.11	-0.04	-0.2	0

ENDP Frequently Asked Questions

What is Endo International plc stock symbol ?

Endo International plc is a IE stock , located in Dublin of Dublin and trading under the symbol ENDP

What is Endo International plc stock quote today ?

Endo International plc stock price is $0.2926 today.

Is Endo International plc stock public?

Yes, Endo International plc is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Employee 3.1K
CEO Mr. Blaise Coleman
Headquarters DUBLIN,DUBLIN,IE
IPO Date 2014-03-03
Website https://www.endo.com

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.